Market Overview
The global cholesterol testing products market reached US$ 19.85 billion in 2024 and is expected to reach US$ 42.25 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.
Cholesterol testing is a vital diagnostic procedure used to measure the levels of cholesterol in the blood, helping to assess the risk of cardiovascular diseases such as heart disease, stroke, and atherosclerosis. Cholesterol testing products are important tools used to measure cholesterol levels in the blood, playing a vital role in detecting, preventing, and managing cardiovascular diseases.
These products come in various forms, from traditional lab-based kits to more convenient point-of-care devices and at-home testing kits, giving both individuals and healthcare providers easy access to monitor cholesterol levels. By measuring key components like LDL (bad cholesterol) and HDL (good cholesterol), these products help evaluate the risk of heart disease and guide treatment plans to improve heart health. With the growing awareness of heart health, the demand for these cholesterol testing products is increasing, supporting proactive and preventive care.
Executive Summary
Market Dynamics: Drivers & Restraints
Rising Incidence of Cardiovascular Diseases
The growing number of people affected by cardiovascular diseases (CVDs) is a key factor driving the demand for cholesterol testing. With heart disease and strokes being the leading causes of death around the world, there's a rising awareness about how crucial it is to keep cholesterol levels in check to maintain heart health. High cholesterol is a major contributor to these conditions, making regular cholesterol testing an important step for both healthcare professionals and individuals who want to prevent serious health issues.
As more people are diagnosed with related conditions like high blood pressure, obesity, and diabetes there’s a greater need for reliable and easy-to-use cholesterol testing tools. This growing awareness and focus on early detection are expected to boost the cholesterol testing market, with more people actively seeking ways to monitor and manage their cholesterol to lower the risk of cardiovascular problems.
High Costs of Treatment
The high cost of advanced cholesterol testing devices can significantly hinder the growth of the cholesterol testing products market, especially in low-income regions or for smaller healthcare providers. Many advanced cholesterol testing devices, such as those used in professional labs or specialized point-of-care testing equipment, require significant upfront investment. These devices often come with high maintenance costs, training requirements for proper usage, and the need for regular calibration to ensure accuracy.
For more details on this report – Request for Sample
Segment Analysis
The global cholesterol testing products market is segmented based on procedure type, device type, surgery type, indication, end-user, and region.
Treatment:
Devices segment is expected to dominate the global cholesterol testing products market share
The devices segment is expected to dominate the cholesterol testing products market due to a combination of technological advancements, growing consumer demand for at-home testing, and the increasing focus on preventive healthcare. With innovations in point-of-care testing devices and self-monitoring kits, cholesterol testing has become more accurate, accessible, and convenient, allowing individuals to monitor their cholesterol levels from the comfort of their homes.
The integration of these devices with mobile apps and digital health platforms further enhances their appeal by enabling real-time tracking and personalized health insights. As the shift toward proactive health management continues, cholesterol testing devices are becoming essential tools for both healthcare professionals and consumers, driving widespread adoption and market growth. Their ability to provide quick, reliable results at an affordable cost positions them as the leading solution in the market.
Geographical Analysis
North America is expected to hold a significant position in the global cholesterol testing products market share
North America is leading the cholesterol testing products market due to high levels of awareness about heart health, and a strong emphasis on preventive care. The region benefits from well-established healthcare systems, widespread access to cutting-edge medical devices, and a growing focus on early detection and management of cardiovascular diseases. In addition, both the U.S. and Canada have robust health insurance systems that often cover the cost of cholesterol testing, making it more accessible to the general population.
The increasing prevalence of high cholesterol, coupled with rising healthcare awareness campaigns, has driven the adoption of cholesterol testing products, further solidifying North America's dominance in the market. For instance, according to the Tebra Inc. in 2024, approximately 71 million Americans have high cholesterol, and although there are many potential causes, one key factor is that certain habits can raise cholesterol levels without people even realizing it. Furthermore, the integration of innovative technologies like point-of-care testing devices and digital health solutions has contributed to the region's leadership in cholesterol monitoring.
Competitive Landscape
The major global players in the cholesterol testing products market include Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers GmbH, ACON Laboratories Inc., Lepu Medical Technology (Beijing)Co., Ltd., SD Biosensor, INC., Recombigen Laboratories Pvt. Ltd, Assure Tech (Hangzhou) Co., Ltd., V.P. Healthcare and SG Diagnostics among others.
| Metrics | Details | |
| CAGR | 8.8% | |
| Market Size Available for Years | 2022-2033 | |
| Estimation Forecast Period | 2025-2033 | |
| Revenue Units | Value (US$ Bn) | |
| Segments Covered | Product | Devices, Test Kits, Others |
| Test Type | Total Cholesterol Tests, Low Density-Lipoprotein (LDL) Cholesterol Tests, High-Density Lipoprotein (HDL) Cholesterol Tests, Triglycerides Tests, Others | |
| Application | Cardiovascular Diseases, Diabetes, Obesity, Hyperlipidemia, Others | |
| End User | Hospitals, Diagnostic Centers, Home Healthcare, Research Laboratories | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Key Developments
- In August 2024, AstraZeneca's Imfinzi (durvalumab) received approval in the United States for use in combination with chemotherapy to treat adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
- In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have a BRAF V600E mutation, as identified by an FDA-approved test. This approval provides a new personalized treatment option for patients with this specific mutation in their cancer.
- In August 2023, Eli Lilly and Company announced the topline results from the LIBRETTO-431 study, which evaluated Retevmo (selpercatinib) against platinum-based chemotherapy plus pemetrexed as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC).
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Global Cholesterol Testing Products Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2025
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
